Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RBD4059
- Development stage
- Phase 2
- Lead developer
- Suzhou Ribo Life Science
- Modality
- Small Molecules, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Subcutaneous
01
Overview
RBD4059 is a GalNAc-conjugated small interfering RNA (siRNA) drug developed to target and inhibit coagulation factor XI (FXI) in the liver. By silencing FXI mRNA in hepatocytes, RBD4059 reduces FXI protein levels, thereby exerting potent antithrombotic effects with a low risk of bleeding. The drug leverages the RIBO-GalSTAR technology platform for targeted delivery to the liver, enabling durable pharmacodynamic effects and infrequent dosing regimens (every 3–6 months). RBD4059 is being developed primarily for conditions requiring anticoagulation, such as thromboembolism and coronary artery disease. Preclinical and early clinical studies have demonstrated significant reductions in FXI activity (>90%) with favorable safety profiles and no clinically relevant bleeding events[2][3][5][6][7].
- Other names
- rbd-4059rbd4059rbd 4059
02
Targets
F11 (Coagulation Factor XI)
Beyond the preview
Go deeper on RBD4059.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RBD4059.